AU2015231226B2 - Antifungal compound process - Google Patents

Antifungal compound process Download PDF

Info

Publication number
AU2015231226B2
AU2015231226B2 AU2015231226A AU2015231226A AU2015231226B2 AU 2015231226 B2 AU2015231226 B2 AU 2015231226B2 AU 2015231226 A AU2015231226 A AU 2015231226A AU 2015231226 A AU2015231226 A AU 2015231226A AU 2015231226 B2 AU2015231226 B2 AU 2015231226B2
Authority
AU
Australia
Prior art keywords
mixture
alcohol
amino
compound
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015231226A
Other languages
English (en)
Other versions
AU2015231226A1 (en
Inventor
Asaf Alimardanov
Mark Behnke
Scott A. David
Douglas Franklin Fry
William J. Hoekstra
Christopher M. Yates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mycovia Pharmaceuticals Inc
US Department of Health and Human Services
Original Assignee
Mycovia Pharmaceuticals Inc
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mycovia Pharmaceuticals Inc, Government of the United States of America filed Critical Mycovia Pharmaceuticals Inc
Publication of AU2015231226A1 publication Critical patent/AU2015231226A1/en
Assigned to THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES, Viamet Pharmaceuticals (NC), Inc. reassignment THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES Amend patent request/document other than specification (104) Assignors: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES, VIAMET PHARMACEUTICALS, INC.
Assigned to THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES, Mycovia Pharmaceuticals, Inc. reassignment THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES Amend patent request/document other than specification (104) Assignors: Viamet Pharmaceuticals (NC), Inc., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES
Application granted granted Critical
Publication of AU2015231226B2 publication Critical patent/AU2015231226B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/26—Radicals substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Artificial Filaments (AREA)
AU2015231226A 2014-03-19 2015-03-19 Antifungal compound process Ceased AU2015231226B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461955615P 2014-03-19 2014-03-19
US61/955,615 2014-03-19
PCT/US2015/021491 WO2015143172A1 (en) 2014-03-19 2015-03-19 Antifungal compound process

Publications (2)

Publication Number Publication Date
AU2015231226A1 AU2015231226A1 (en) 2016-10-06
AU2015231226B2 true AU2015231226B2 (en) 2019-04-04

Family

ID=54145323

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015231226A Ceased AU2015231226B2 (en) 2014-03-19 2015-03-19 Antifungal compound process

Country Status (14)

Country Link
US (2) US10173998B2 (enExample)
EP (1) EP3119745B1 (enExample)
JP (1) JP6509897B2 (enExample)
KR (1) KR102151082B1 (enExample)
CN (2) CN106458900B (enExample)
AU (1) AU2015231226B2 (enExample)
BR (1) BR112016020937B1 (enExample)
CA (1) CA2942968C (enExample)
EA (1) EA037587B1 (enExample)
ES (1) ES2815373T3 (enExample)
HU (1) HUE052446T2 (enExample)
MX (1) MX365494B (enExample)
PL (1) PL3119745T3 (enExample)
WO (1) WO2015143172A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6572234B2 (ja) * 2014-03-19 2019-09-04 ヴィアメット ファーマスーティカルズ（エヌシー），インコーポレイテッド 抗真菌化合物の調製方法
AU2015231275B2 (en) 2014-03-19 2019-03-07 Mycovia Pharmaceuticals, Inc. Antifungal compound process
KR102441243B1 (ko) 2014-03-19 2022-09-07 브이피에스-3, 엘엘씨 2-(2,4-디플루오르페닐)-1,1-디플루오르-1-(5-치환된-피리딘-2-일)-3-(1h-테트라졸-1-일)프로판-2-올 및 이의 제조방법
AU2015231208B2 (en) * 2014-03-19 2019-04-04 Mycovia Pharmaceuticals, Inc. Antifungal compound process
CA2942936A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
EP3119753B1 (en) 2014-03-19 2020-11-04 Dow AgroSciences LLC 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation
WO2015143180A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
CA2942231A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
DK3271347T3 (da) * 2015-03-19 2022-07-18 Mycovia Pharmaceuticals Inc Antifungale forbindelser og fremstillingsfremgangsmåder
HK1263287A1 (zh) * 2015-09-18 2020-03-20 Nqp 1598, Ltd. 抗真菌化合物和制备方法
US11213031B2 (en) 2017-11-13 2022-01-04 Bayer Aktiengesellschaft Tetrazolylpropyl derivatives and their use as fungicides
AU2019325436B2 (en) * 2018-08-18 2023-10-26 5Metis, Inc. Solid forms of substituted benzoxaborole and compositions thereof
CN114573557B (zh) * 2022-03-28 2024-03-08 浙江天宇药业股份有限公司 一种奥特康唑的制备方法
CN116621816B (zh) * 2022-09-23 2025-07-04 北京莱瑞森医药科技有限公司 一种伏立康唑对映异构对b的拆分方法
CN116675672B (zh) * 2023-06-05 2025-04-25 北京康立生医药技术开发有限公司 一种抗真菌药物的制备方法
CN119798219B (zh) * 2025-01-13 2025-07-18 长治医学院 一种奥特康唑的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011133875A2 (en) * 2010-04-24 2011-10-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
WO2012177608A1 (en) * 2011-06-19 2012-12-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2854015B2 (de) 1978-12-14 1980-10-09 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur Herstellung von !H-TetrazoI-1-essigsauren und bestimmter Ester derselben
JP2000344744A (ja) 1999-06-04 2000-12-12 Ss Pharmaceut Co Ltd アセトフェノン誘導体およびその製法
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
KR100889937B1 (ko) 2007-08-06 2009-03-20 한미약품 주식회사 보리코나졸의 제조방법
KR101109215B1 (ko) 2009-06-17 2012-01-30 보령제약 주식회사 보리코나졸의 신규 중간체 및 이를 이용한 보리코나졸의 제조방법
CN102803232A (zh) 2009-06-18 2012-11-28 巴斯夫欧洲公司 杀真菌的具有5-硫取代基的1,2,4-三唑衍生物
BR122020013521B1 (pt) 2011-06-19 2021-05-25 Viamet Pharmaceuticals (NC), Inc compostos inibidores de metaloenzima
CN103930418A (zh) 2011-06-23 2014-07-16 威尔金制药有限公司 金属酶抑制剂化合物
BR112014013963B1 (pt) * 2011-12-11 2021-06-22 Nqp 1598, Ltd Compostos inibidores de metaloenzimas, composições compreendendo os ditos compostos, uso terapêutico dos mesmos e métodos para inibir a atividade de metaloenzimas e para tratar ou prevenir o crescimento de fungos em plantas
DK2804858T3 (da) * 2012-01-20 2020-03-16 Mycovia Pharmaceuticals Inc Metalloenzym-inhibitorforbindelser
EP2804479A4 (en) 2012-01-20 2015-07-22 Viamet Pharmaceuticals Inc METALLOENZYME INHIBITOR COMPOUNDS
WO2014043376A1 (en) 2012-09-12 2014-03-20 Dow Agrosciences Llc Metalloenzyme inhibitor compounds
WO2014117090A1 (en) 2013-01-28 2014-07-31 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
WO2014165861A1 (en) 2013-04-05 2014-10-09 The Regents Of The University Of California Metal-catalyzed coupling of aryl and vinyl halides with alpha, alpha-difluorocarbonyl compounds
WO2014193974A1 (en) 2013-05-28 2014-12-04 Viamet Pharmaceuticals, Inc. Fungicidal compositions
KR20160018811A (ko) 2013-06-12 2016-02-17 비아멧 파마슈티컬즈, 인코포레이티드 금속 효소 억제 화합물
CA2942936A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
JP6572234B2 (ja) 2014-03-19 2019-09-04 ヴィアメット ファーマスーティカルズ（エヌシー），インコーポレイテッド 抗真菌化合物の調製方法
WO2015143180A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
AU2015231275B2 (en) 2014-03-19 2019-03-07 Mycovia Pharmaceuticals, Inc. Antifungal compound process
CA2942231A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
KR102441243B1 (ko) 2014-03-19 2022-09-07 브이피에스-3, 엘엘씨 2-(2,4-디플루오르페닐)-1,1-디플루오르-1-(5-치환된-피리딘-2-일)-3-(1h-테트라졸-1-일)프로판-2-올 및 이의 제조방법
AU2015231208B2 (en) 2014-03-19 2019-04-04 Mycovia Pharmaceuticals, Inc. Antifungal compound process
US9802914B2 (en) 2014-03-19 2017-10-31 Viamet Pharmaceuticals, Inc. Antifungal compound process
EP3119753B1 (en) 2014-03-19 2020-11-04 Dow AgroSciences LLC 2-(2,4-difluorophenyl)-1,1-difluoro-1-(5-substituted-pyridin-2-yl)-3-(1h-tetrazol-1-yl)propan-2-ols and processes for their preparation
DK3271347T3 (da) 2015-03-19 2022-07-18 Mycovia Pharmaceuticals Inc Antifungale forbindelser og fremstillingsfremgangsmåder
KR20180000731A (ko) 2015-05-18 2018-01-03 비아멧 파마슈티컬즈, 인코포레이티드 항진균성 화합물
HK1263287A1 (zh) 2015-09-18 2020-03-20 Nqp 1598, Ltd. 抗真菌化合物和制备方法
CA3005743A1 (en) 2015-11-17 2017-05-26 Dow Agrosciences Llc 4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1h-1,2,4-triazol-1-yl)propyl)pyridin-3-yl)oxy)benzonitrile and processes of preparation
JP6963557B2 (ja) 2015-11-17 2021-11-10 コルテバ アグリサイエンス エルエルシー ４−（（６−（２−（２，４−ジフルオロフェニル）−１，１−ジフルオロ−２−ヒドロキシ−３−（１ｈ−１，２，４−トリアゾール−１−イル）プロピル）ピリジン−３−イル）オキシ）ベンゾニトリル及び調製方法
KR20180101343A (ko) 2015-11-17 2018-09-12 다우 아그로사이언시즈 엘엘씨 4-((6-(2-(2,4-디플루오로페닐)-1,1-디플루오로-2-옥소에틸)피리딘-3-일)옥시)벤조니트릴 및 제조방법
EP3377475A4 (en) 2015-11-17 2019-04-10 Dow Agrosciences Llc 4 - ((6-2- (2,4-difluorophenyl) -1,1-difluoro-2-hydroxy-3- (1H-1,2,4-triazol-1-YL) PROPYL) PYRIDINE-3-YL ) OXY) BENZONITRIL AND METHOD OF PREPARING THEREOF
EA038421B1 (ru) 2015-12-30 2021-08-26 ВиПиЭс-3, ИНК. Соединения, ингибирующие металлоферменты

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011133875A2 (en) * 2010-04-24 2011-10-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
WO2012177608A1 (en) * 2011-06-19 2012-12-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds

Also Published As

Publication number Publication date
EP3119745A1 (en) 2017-01-25
MX2016012056A (es) 2017-04-27
HUE052446T2 (hu) 2021-04-28
JP6509897B2 (ja) 2019-05-08
WO2015143172A1 (en) 2015-09-24
CN106458900A (zh) 2017-02-22
US10392365B2 (en) 2019-08-27
CA2942968A1 (en) 2015-09-24
EP3119745A4 (en) 2017-08-23
BR112016020937B1 (pt) 2022-09-20
AU2015231226A1 (en) 2016-10-06
PL3119745T3 (pl) 2021-01-25
BR112016020937A2 (enExample) 2017-08-15
EA201691649A1 (ru) 2016-12-30
US20170088539A1 (en) 2017-03-30
US10173998B2 (en) 2019-01-08
MX365494B (es) 2019-06-05
US20190161469A1 (en) 2019-05-30
JP2017509644A (ja) 2017-04-06
CN106458900B (zh) 2019-01-01
KR102151082B1 (ko) 2020-09-03
CA2942968C (en) 2022-03-15
KR20160138012A (ko) 2016-12-02
ES2815373T3 (es) 2021-03-29
EA037587B1 (ru) 2021-04-19
EP3119745B1 (en) 2020-08-05
CN109970629A (zh) 2019-07-05
CN109970629B (zh) 2023-04-11

Similar Documents

Publication Publication Date Title
AU2015231226B2 (en) Antifungal compound process
US10836740B2 (en) Antifungal compound process
AU2015231234B2 (en) Antifungal compound process
US10421741B2 (en) Antifungal compound process
AU2015231208B2 (en) Antifungal compound process
HK1257225B (en) Antifungal compound process
HK1263288A1 (en) Antifungal compound process
HK1263288B (en) Antifungal compound process

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH

Free format text: FORMER NAME(S): THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES; VIAMET PHARMACEUTICALS, INC.

Owner name: VIAMET PHARMACEUTICALS (NC), INC.

Free format text: FORMER NAME(S): THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES; VIAMET PHARMACEUTICALS, INC.

HB Alteration of name in register

Owner name: MYCOVIA PHARMACEUTICALS, INC.

Free format text: FORMER NAME(S): VIAMET PHARMACEUTICALS (NC), INC.; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES

Owner name: THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH

Free format text: FORMER NAME(S): VIAMET PHARMACEUTICALS (NC), INC.; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired